The U.S. Supreme Court ruled in favor of Bayer, finding that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempts state laws that would impose labeling requirements beyond what federal regulators mandate. This means plaintiffs cannot use state failure-to-warn claims to argue Roundup needed additional cancer warnings beyond the EPA-approved label — the primary legal theory driving thousands of lawsuits against Bayer.

The ruling is a significant positive for Bayer, whose shares had been weighed down for years by Roundup liability estimates that some analysts pegged north of $10 billion. The company inherited the litigation when it acquired Monsanto in 2018 and has faced wave after wave of jury verdicts. This Supreme Court decision does not extinguish all litigation, but it substantially narrows the path for future claims and may allow Bayer to resolve existing cases at lower costs.

The second-order setup is a potential re-rating of Bayer's litigation discount. Markets had long priced in a worst-case liability scenario, and a ruling of this magnitude could prompt analysts to revise liability estimates downward, lifting the stock's fundamental floor. However, some cases involving other legal theories — such as design defect — may survive preemption and continue to pressure the company.

Key things to watch: how quickly Bayer's legal team moves to dismiss or renegotiate pending settlements, whether plaintiffs' attorneys pivot to non-preempted theories, and any regulatory or congressional reaction that could attempt to override the ruling. The stock's move on the day likely captures only part of the potential re-rating if liability estimates are revised materially lower.